Lucas Pari Mitre

Lucas Pari Mitre

Auto-generated profile, based on publicly available information

Lucas Pari Mitre

Department of Neurosurgery, UT Southwestern Medical Center, Dallas, Texas

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2024 in World Neurosurgery
Verified
Journal Article
Closed access
LMLucas P. Mitre
Lucas P. Mitre
LPLucca B. Palavani
Lucca B. Palavani
SBSávio Batista
Sávio Batista
Filipi AndreãoFilipi Andreão
Filipi Andreão
EMEdson I. Mitre
Edson I. Mitre
MRMarcio S. Rassi
Marcio S. Rassi

14 August 2024 in World Neurosurgery
Verified
Journal Article
Closed access
LPLucca B Palavani
Lucca B Palavani
RCRaphael Camerotte
Raphael Camerotte
LMLucas Pari Mitre
Lucas Pari Mitre
SBSávio Batista
Sávio Batista
IBIsabela Banderali
Isabela Banderali
Jean G. de OliveiraJean G. de Oliveira
Jean G. de Oliveira

27 February 2025 in World Neurosurgery
Verified
Journal Article
Open access
EAEloísa Bittencurt Thomaz de Assis
Eloísa Bittencurt Thomaz de Assis
MFMarcio Yuri Ferreira
Marcio Yuri Ferreira
JOJéssica Sales de Oliveira
Jéssica Sales de Oliveira
LMLucas Pari Mitre
Lucas Pari Mitre
ESEduardo Mendes Correa da Silva
Eduardo Mendes Correa da Silva
APAllan Dias Polverini
Allan Dias Polverini
High-grade gliomas (HGGs) are aggressive tumors known for their poor prognosis. Despite research into its molecular and clinical aspects, current management minimally impacts survival. It is unclear whether combining temozolomide (TMZ) with metformin (MET) could enhance survival in this population. A systematic search on PubMed, Embase, and Cochrane Library databases was conducted for studies comparing TMZ+MET versus TMZ alone for HGG. The outcomes of interest were overall survival, progression-free survival, and subgroup analysis with O6-methylguanine-DNA methyltransferase and patients with diabetes. The analysis comprised outcomes reported as hazard ratios (HRs) and odds ratios with corresponding 95% confidence intervals (CIs) as all the outcomes are continuous. A significance level of P < 0.05 was considered statistically significant. Heterogeneity was assessed using the I2 statistic with P values inferior to 0.10, and I2 > 25% were considered significant for heterogeneity. The random effects model was employed for all outcomes. Ten studies were included, comprising 3623 patients, of which 346 (9.5%) were assigned for TMZ+MET. The TMZ+MET group was associated with a significant reduction in mortality rates when compared to the TMZ alone group (HR 0.74; 95% CI 0.59, 0.93; P < 0.01; I2 29%). There was no significant difference between groups for progression-free survival (HR 0.87; 95% CI 0.68-1.12; P = 0.29). In a subgroup analysis restricted to patients who received TMZ+MET, the diabetic subgroup had a significantly higher mortality rate than the normoglycemic subgroup (odds ratio 1.25; 95% CI 1.10, 1.41; P < 0.01; I2 79%). Our results showed that patients who received TMZ+MET had a significantly higher overall survival than patients who received TMZ alone. These findings support the use of MET along with TMZ for the treatment of HGGs.

5 January 2024 in World Neurosurgery
Verified
Journal Article
Closed access
MFMarcio Yuri Ferreira
Marcio Yuri Ferreira
EAEloísa Bittencurt Thomaz de Assis
Eloísa Bittencurt Thomaz de Assis
SBSavio Batista
Savio Batista
LPLucca B. Palavani
Lucca B. Palavani
GVGabriel Verly
Gabriel Verly
APAllan Dias Polverini
Allan Dias Polverini

2 May 2025 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
Aladine A. ElsamadicyAladine A. Elsamadicy
Aladine A. Elsamadicy
PSPaul Serrato
Paul Serrato
SGShaila D. Ghanekar
Shaila D. Ghanekar
SSSina Sadeghzadeh
Sina Sadeghzadeh
JHJustice Hansen
Justice Hansen
Daniel M. SciubbaDaniel M. Sciubba
Daniel M. Sciubba

23 January 2026 in Global Spine Journal
Verified
Journal Article
Open access
LMLucas P Mitre
Lucas P Mitre
RSRômulo S Sanglard
Rômulo S Sanglard
EBEthan D. L. Brown D.L. Brown
Ethan D. L. Brown D.L. Brown
SGShaila D Ghanekar
Shaila D Ghanekar
PSPaul Serrato
Paul Serrato
AEAladine A Elsamadicy
Aladine A Elsamadicy
Study Design: Systematic review and meta-analysis. Objective: Direct head-to-head comparison of machine learning models aiming to predict outcomes in Anterior Cervical Discectomy and Fusion (ACDF) is necessary because existing studies typically evaluate algorithms in isolation, using heterogeneous datasets, features, and performance metrics, which limits interpretability and prevents meaningful comparison of predictive performance. Methods: We conducted a systematic review and meta-analysis according to PRISMA guidelines, searching PubMed, Embase, Web of Science and Cochrane through December 2024. We identified 26 studies (n = 443 445 patients) that developed ML models for ACDF outcomes. Algorithms were categorized into five classes by taxonomy: Logistic regression, tree-based, boosting ensembles, kernel methods and NNs. Pooled ML models’ AUCs and accuracy were extracted and estimated via random-effects inverse-variance model. Results: Overall discrimination ranged from 0.59 for major complications to 0.81 for adjacent-level disease. Logistic regression led in predicting unfavorable discharge (AUC 0.76), readmission/reintervention (0.68) and cost of care (0.83). Boosting ensembles excelled in predicting thromboembolic events (AUC 0.74; 0.68-0.80; P < 0.0001). Neural networks achieved the highest discrimination for opioid prescription (AUC 0.80; 0.75-0.85; P = 0.02) and adjacent-level disease (AUC 0.81; 0.72-0.91; P < 0.01). Kernel methods delivered an exceptional AUC of 0.97 (0.96-0.97) for adjacent-level fusion but underperformed for other outcomes (AUC 0.43-0.49). Decision-tree and mixed-ensemble approaches demonstrated intermediate performance for various outcomes (AUC range 0.54-0.75). Conclusion: Logistic regression and gradient-boosting models offer robust, generalizable discrimination across diverse ACDF outcomes. Neural networks and kernel methods showed endpoint-specific strengths. These data support prospective validation and rapid integration of ML-driven risk calculators into perioperative workflows.